204452-93-7

Usage

Uses

Used in Pharmaceutical Industry:
5,6,7,8-tetrahydro-1,8-naphthyridine-2-carbaldehyde is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activities and ability to contribute to the development of new drugs.
Used in Organic Synthesis:
5,6,7,8-tetrahydro-1,8-naphthyridine-2-carbaldehyde is used as a precursor in the synthesis of other valuable organic compounds, leveraging its unique chemical structure and properties.
Used in Antibacterial Applications:
5,6,7,8-tetrahydro-1,8-naphthyridine-2-carbaldehyde is used as an antibacterial agent due to its potential biological activities, offering a promising alternative for combating bacterial infections.
Used in Antifungal Applications:
5,6,7,8-tetrahydro-1,8-naphthyridine-2-carbaldehyde is used as an antifungal agent, harnessing its potential biological activities to address fungal infections and related health concerns.

InChI:InChI=1/C9H10N2O/c12-6-8-4-3-7-2-1-5-10-9(7)11-8/h3-4,6H,1-2,5H2,(H,10,11)

Upstream product

• 204452-90-4 2-(dimethoxymethyl)-1,8-naphthyridine 
• 204452-91-5 3(S)-(6-methoxypyridin-3-yl)-3-alanine tert-butyl ester p-toluenesulfonic acid 
• 7521-41-7 2-Aminonicotinaldehyde 

Downstream Products

• 227963-15-7 (S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid 
• 206989-41-5 3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propane-1-amine 
• 381678-78-0 (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)methanol 

Relevant academic research and scientific papers

COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administrat

PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, and Q are defined herein.

Prokineticin 1 receptor antagonists

The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

PROKINETICIN 2 RECEPTOR ANTAGONISTS

The present invention relates to certain novel compounds of Formula (I): and methods for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders.

An efficient synthesis of an alphavbeta3 antagonist.

A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was p

1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof

Certain 1-(aromatic- or heteroaromatic-substituted-3-(heteroaromatic substituted)-1,3-propanediones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.